Patents by Inventor Louis Monti
Louis Monti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11419881Abstract: 16?,17?-Epoxy-10?-hydroxyestr-4-en-3-one is useful in the treatment of migraine by nasal administration.Type: GrantFiled: April 7, 2020Date of Patent: August 23, 2022Assignee: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti
-
Publication number: 20200323884Abstract: 16?,17?-Epoxy-10?-hydroxyestr-4-en-3-one is useful in the treatment of migraine by nasal administration.Type: ApplicationFiled: April 7, 2020Publication date: October 15, 2020Applicant: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti
-
Patent number: 10322138Abstract: Pregn-4-en-20-yn-3?-one is useful in the treatment of depressive disorders by nasal administration.Type: GrantFiled: December 19, 2013Date of Patent: June 18, 2019Assignee: PHERIN PHARMACEUTICALS, INC.Inventor: Louis Monti
-
Publication number: 20140187524Abstract: Pregn-4-en-20-yn-3?-one is useful in the treatment of depressive disorders by nasal administration.Type: ApplicationFiled: December 19, 2013Publication date: July 3, 2014Applicant: PHERIN PHARMACEUTICALS, INC.Inventor: LOUIS MONTI
-
Patent number: 8722652Abstract: Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3?]-androsta-4,16-dien-3-ol.Type: GrantFiled: August 13, 2012Date of Patent: May 13, 2014Assignee: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti-Bloch
-
Publication number: 20130172305Abstract: Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3?]-androsta-4,16-dien-3-ol.Type: ApplicationFiled: August 13, 2012Publication date: July 4, 2013Inventor: Louis Monti-Bloch
-
Patent number: 8431559Abstract: 16?,17?-Epoxy-10?-hydroxyestr-4-en-3-one is useful in the treatment of hot flashes by vomeronasal administration.Type: GrantFiled: November 3, 2011Date of Patent: April 30, 2013Assignee: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti
-
Patent number: 8309539Abstract: Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3?]-androsta-4,16-dien-3-ol.Type: GrantFiled: September 9, 2005Date of Patent: November 13, 2012Assignee: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti-Bloch
-
Publication number: 20120108558Abstract: 16?,17?-Epoxy-10?-hydroxyestr-4-en-3-one is useful in the treatment of hot flashes by vomeronasal administration.Type: ApplicationFiled: November 3, 2011Publication date: May 3, 2012Inventor: Louis Monti
-
Publication number: 20090258040Abstract: Embodiments of the invention relate to methods for treating individuals suffering from hot flashes by vomeronasally administering a therapeutically effective dosage of a steroid agent. The hot flashes may be a result of postmenopause or castration suffered by the individual. In many embodiments, the method for treating individuals suffering with hot flashes is provided by administering a steroid agent containing an estrene compound, such as 16?,17?-epoxy-10?-hydroxyestr-4-en-3-one, to the individual. In other embodiments, pharmaceutical compositions containing the steroid agent may be used to treat individuals suffering with hot flashes. Embodiments include methods for treating male castrates, as well as postmenopausal women and men, suffering from hot flashes by vomeronasally administering a steroid agent containing 16?,17?-epoxy-10?-hydroxyestr-4-en-3-one to levitate the hot flashes.Type: ApplicationFiled: April 9, 2009Publication date: October 15, 2009Applicant: PHERIN PHARMACEUTICALS, INC.Inventor: Louis Monti
-
Publication number: 20090075964Abstract: This invention is generally related to the fields of fragrance compositions, personal care products, and home consumer products. This invention also relates to 20-pregnenes, in particular those found naturally occurring in corals and which affect mood in humans, to the incorporation of these 20-pregnene compounds into various compositions, and to methods of affecting the mood of individuals using such compounds.Type: ApplicationFiled: September 16, 2008Publication date: March 19, 2009Applicant: Human Pheromone Sciences, Inc.Inventors: Chloe JENNINGS-WHITE, Louis MONTI-BLOCH
-
Publication number: 20070059249Abstract: Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3?]-androsta-4,16-dien-3-ol.Type: ApplicationFiled: September 9, 2005Publication date: March 15, 2007Inventor: Louis Monti-Bloch
-
Publication number: 20030220309Abstract: 17-Methylenandrostan-3&agr;-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methylenandrost-4-en-3&agr;-ol is disclosed.Type: ApplicationFiled: June 13, 2003Publication date: November 27, 2003Applicant: Pherin Pharmaceuticals, Inc.Inventors: Louis Monti, David L. Berliner, Clive L. Jennings-White, Nathan W. Adams
-
Patent number: 6555531Abstract: Pregnanes of formula I, and pharmaceutical compositions and products containing them, are useful in weight promotion by administration to the vomeronasal organ.Type: GrantFiled: December 30, 1999Date of Patent: April 29, 2003Assignee: Pherin Pharmaceuticals, Inc.Inventors: David L. Berliner, Louis Monti, Clive L. Jennings-White
-
Patent number: 6544971Abstract: A method of increasing alertness in an individual by administering an effective amount of an alertness-increasing vomeropherin to the individual; and an alarm device that, when activated, emits an alertness-increasing vomeropherin. The method and device are especially useful in increasing alertness in individuals who are not readily responsive to usual external stimuli.Type: GrantFiled: February 4, 2000Date of Patent: April 8, 2003Assignee: Pherin Pharmaceuticals, Inc.Inventors: David L. Berliner, Louis Monti, Clive L. Jennings-White
-
Publication number: 20030045514Abstract: 17-Methyleneandrostan-3&agr;-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methylenandrost-4-en-3&agr;-ol is disclosed.Type: ApplicationFiled: May 3, 2001Publication date: March 6, 2003Inventors: Louis Monti, David L. Berliner, Clive L. Jennings-White, Nathan W. Adams